ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $4.60 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.92.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.49.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2021-03-31 was $5.23, a 33.80% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $7.90.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $4.96, a 13.24% increase from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $4.38, a 28.90% decline from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $6.16, a 13.12% decline from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $7.09, a 35.56% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.60 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $4.92 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $4.96 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $4.87 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $4.87 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | $4.38 10-K · filed 2025-02-28 | |||
| 2024-09-30 | $4.49 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $4.49 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $4.49 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $6.16 10-K · filed 2024-03-07 | |||
| 2023-09-30 | $5.56 10-Q · filed 2023-11-03 | |||
| 2022-12-31 | $7.09 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $7.09 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $6.19 10-Q · filed 2022-08-05 | |||
| 2021-12-31 | $5.23 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $5.23 10-Q · filed 2021-10-28 | |||
| 2021-06-30 | $5.23 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $5.23 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $6.59 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $6.53 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $6.37 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $7.90 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $7.66 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $7.28 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $7.11 10-Q · filed 2019-08-09 | |||
| 2018-12-31 | $3.24 10-K · filed 2019-03-08 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | $4.02 10-K · filed 2018-03-29 | |||
| 2017-09-30 | $4.02 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $5.60 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $6.30 10-K · filed 2017-03-30 | |||
| 2016-09-30 | $5.68 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $5.97 10-Q · filed 2016-08-10 | |||
| 2016-03-31 | $5.23 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |